These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 28222316)
1. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Horley NJ; Beresford KJ; Chawla T; McCann GJ; Ruparelia KC; Gatchie L; Sonawane VR; Williams IS; Tan HL; Joshi P; Bharate SS; Kumar V; Bharate SB; Chaudhuri B Eur J Med Chem; 2017 Mar; 129():159-174. PubMed ID: 28222316 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350 [TBL] [Abstract][Full Text] [Related]
5. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468 [TBL] [Abstract][Full Text] [Related]
6. Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells. Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB J Chem Inf Model; 2017 Jun; 57(6):1309-1320. PubMed ID: 28489395 [TBL] [Abstract][Full Text] [Related]
7. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398 [TBL] [Abstract][Full Text] [Related]
8. (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent. Horley NJ; Beresford KJM; Kaduskar S; Joshi P; McCann GJP; Ruparelia KC; Williams IS; Gatchie L; Sonawane VR; Bharate SB; Chaudhuri B Bioorg Med Chem Lett; 2017 Dec; 27(24):5409-5414. PubMed ID: 29138024 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors. Dong J; Wang Z; Cui J; Meng Q; Li S Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634 [TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression. Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264 [TBL] [Abstract][Full Text] [Related]
11. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300 [TBL] [Abstract][Full Text] [Related]
12. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors. Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055 [TBL] [Abstract][Full Text] [Related]
13. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells. Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599 [TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Chun YJ; Oh YK; Kim BJ; Kim D; Kim SS; Choi HK; Kim MY Toxicol Lett; 2009 Aug; 189(1):84-9. PubMed ID: 19463925 [TBL] [Abstract][Full Text] [Related]
15. A new class of CYP1B1 inhibitors derived from bentranil. Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. Chang TK; Chen J; Yang G; Yeung EY J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601 [TBL] [Abstract][Full Text] [Related]
17. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs. Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665 [TBL] [Abstract][Full Text] [Related]
19. In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study. Sharma H; Raju B; Narendra G; Kumar M; Verma H; Sharma B; Tung GK; Kumar Jain S; Brás NF; Silakari O J Mol Graph Model; 2023 Mar; 119():108390. PubMed ID: 36502606 [TBL] [Abstract][Full Text] [Related]
20. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Chang TK; Chen J; Yeung EY Toxicol Appl Pharmacol; 2006 May; 213(1):18-26. PubMed ID: 16226778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]